Keywords:
Botulinum toxin A (Hugel), Botulinum toxin A (Hugel)’s R&D Progress, Mechanism of Action for Botulinum toxin A (Hugel), drug target for Botulinum toxin A (Hugel).
Description:
This article summarized the latest R&D progress of Botulinum toxin A (Hugel), the Mechanism of Action for Botulinum toxin A (Hugel), and the drug target R&D trends for Botulinum toxin A (Hugel).
Text:
Botulinum toxin A (Hugel)‘s R&D Progress
Botulinum toxin A (Hugel) is a drug classified as a toxin and is primarily used in the field of biomedicine. It targets SNAP25, a protein involved in the release of neurotransmitters. The drug has been approved for various therapeutic areas including Nervous System Diseases, Urogenital Diseases, Skin and Musculoskeletal Diseases, Other Diseases, and Eye Diseases.
The active indications for Botulinum toxin A (Hugel) include Glabellar frown lines, Blepharospasm, Facial wrinkles, Cerebral Palsy, Hypertrophy of Masticatory Muscles, Muscular Diseases, Urinary Bladder Overactive, and Torticollis. These indications cover a wide range of conditions affecting different parts of the body, such as the face, muscles, and urinary bladder.
The drug was developed by Hugel, Inc., an originator organization in the pharmaceutical industry. It has received approval for use in various countries, including South Korea, where it was first approved in February 2010. Botulinum toxin A (Hugel) has also achieved the highest phase of approval globally.
Botulinum toxin A (Hugel) is commonly used for cosmetic purposes, such as reducing the appearance of facial wrinkles and frown lines. It is also utilized in the treatment of medical conditions like Blepharospasm (involuntary eyelid twitching), Cerebral Palsy (a group of disorders affecting movement and muscle tone), and Torticollis (a condition causing neck muscles to contract involuntarily).
Additionally, the drug is used to manage conditions related to the urinary bladder, including Overactive Bladder. It can help alleviate symptoms such as frequent urination and urgency.
Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.
Mechanism of Action for Botulinum toxin A (Hugel): SNAP inhibitors
SNAP inhibitors are a type of drugs that specifically target and inhibit the activity of SNAP (Soluble NSF Attachment Protein) proteins. SNAP proteins are involved in the process of membrane fusion, which is crucial for various cellular functions, including neurotransmitter release in the nervous system. By inhibiting SNAP proteins, SNAP inhibitors can modulate neurotransmission and have potential therapeutic applications in conditions such as epilepsy, chronic pain, and neurodegenerative disorders. From a biomedical perspective, SNAP inhibitors are being explored as a potential pharmacological intervention to regulate neurotransmitter release and restore normal neuronal function.
Drug Target R&D Trends for Botulinum toxin A (Hugel)
SNAP25, also known as synaptosomal-associated protein 25, plays a crucial role in the human body’s nervous system. It is a key component of the SNARE complex, which is responsible for the fusion of synaptic vesicles with the presynaptic membrane during neurotransmitter release. SNAP25 facilitates the docking and fusion of vesicles, allowing the release of neurotransmitters that enable communication between neurons. This protein is essential for various physiological processes, including cognition, memory, and motor control. Dysregulation of SNAP25 has been associated with neurological disorders such as epilepsy, attention deficit hyperactivity disorder (ADHD), and schizophrenia. Understanding the role of SNAP25 is vital for developing therapeutic interventions targeting these conditions.
According to Patsnap Synapse, as of 10 Oct 2023, there are a total of 27 SNAP25 drugs worldwide, from 54 organizations, covering 61 indications, and conducting 1023 clinical trials.
Please click on the picture link below for free registration or log in directly if you have a freemium account, you can browse the latest research progress on drugs, indications, organizations, clinical trials, clinical results, and drug patents related to this target
Conclusion
Overall, Botulinum toxin A (Hugel) is a well-established drug with a diverse range of therapeutic applications. Its approval in multiple countries and its high phase of development indicate its effectiveness and safety. The drug’s originator organization, Hugel, Inc., has played a significant role in its development and commercialization.
